Literature DB >> 21630355

Inhibitory control during smooth pursuit in Parkinson's disease and Huntington's disease.

Tracy Henderson1, Nellie Georgiou-Karistianis, Owen White, Lynette Millist, David R Williams, Andrew Churchyard, Joanne Fielding.   

Abstract

The basal ganglia are involved in the preferential selection and suppression of competing responses. Parkinson's disease and Huntington's disease are 2 prototypical basal ganglia disorders that feature impaired inhibitory control, a function of poor conflict resolution. Previous saccadic studies showed that individuals with Parkinson's disease experience difficulty suppressing unwanted ocular motor responses, whereas evidence for a similar difficulty in Huntington's disease is more equivocal. Relative to saccades, few research studies have examined inhibitory control processes in the context of an ongoing smooth pursuit task. In this study, we examined the ability of 16 patients with Parkinson's disease and 12 patients with Huntington's disease to suppress automatic responses to irrelevant distracters that transiently appeared during the tracking of a moving visual stimulus. Compared with an equivalent number of age-matched controls, patients with Parkinson's disease generated proportionately more saccades to distracter stimuli. This was particularly evident for distracters appearing far away from the target. Conversely, whereas individuals with early-stage Huntington's disease and healthy controls made a comparable number of errors toward distracter stimuli, those in a more advanced clinical stage demonstrated significantly poorer inhibitory control. The current findings in parkinsonian patients replicate those previously reported in the saccadic and manual response literature, demonstrating difficulty inhibiting a competing motor response. However, in Huntington's disease we demonstrate for the first time that inhibitory control declines in more advanced-disease stages. This suggests that ocular motility may provide a sensitive marker of clinical disease progression in Huntington's disease.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21630355     DOI: 10.1002/mds.23757

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Disruption of response inhibition circuits in prodromal Huntington disease.

Authors:  Julia A Rao; Deborah L Harrington; Sally Durgerian; Christine Reece; Lyla Mourany; Katherine Koenig; Mark J Lowe; Vincent A Magnotta; Jeffrey D Long; Hans J Johnson; Jane S Paulsen; Stephen M Rao
Journal:  Cortex       Date:  2014-06-02       Impact factor: 4.027

Review 2.  Eye movements in patients with neurodegenerative disorders.

Authors:  Tim J Anderson; Michael R MacAskill
Journal:  Nat Rev Neurol       Date:  2013-01-22       Impact factor: 42.937

3.  Basic and translational neuro-ophthalmology of visually guided saccades: disorders of velocity.

Authors:  Sushant Puri; Aasef G Shaikh
Journal:  Expert Rev Ophthalmol       Date:  2017-11-28

4.  Abnormal Visual Scanning of Emotionally Evocative Natural Scenes in Huntington's Disease.

Authors:  Catarina C Kordsachia; Izelle Labuschagne; Julie C Stout
Journal:  Front Psychol       Date:  2017-03-29

5.  Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task.

Authors:  Thomas Hunefeldt; Sabrina Maffi; Simone Migliore; Ferdinando Squitieri; Marta Olivetti Belardinelli
Journal:  Neural Regen Res       Date:  2020-08       Impact factor: 5.135

6.  The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington's disease individuals.

Authors:  Filipa Júlio; Gina Caetano; Cristina Januário; Miguel Castelo-Branco
Journal:  Orphanet J Rare Dis       Date:  2019-11-08       Impact factor: 4.123

7.  Safety, pharmacokinetics and pharmacodynamics of SBT-020 in patients with early stage Huntington's disease, a 2-part study.

Authors:  Marcus P J van Diemen; Ellen P Hart; Anthony Abbruscato; Liz Mead; Ilse van Beelen; Sandrin C Bergheanu; Pieter W Hameeteman; Emma Coppen; Jessica Y Winder; Matthijs Moerland; Hermien Kan; Jeroen van der Grond; Andrew Webb; Raymund A C Roos; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2020-12-29       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.